Archive for July 22nd, 2014
The Juvenile Diabetes Research Fund (JDRF) recently announced plans to seek a clinical trial to study a new cell replacement therapy to treat type 1 diabetes. JDRF, the leading type 1 diabetes research and advocacy group, is working with the drug company ViaCyte on the new therapy process.
JDRF and ViaCyte are collaborating on what they are calling the VC-01 therapy. ViaCyte has already submitted a MAF (Medical Device Master File) with the Food and Drug Administration for Encaptra, the drug delivery system that VC-01 uses.
The therapy seeks to mimic what the pancreas does in healthy people. Immature pancreatic cells are implanted under the skin inside of a thin plastic pouch. As they mature, the implanted cells should be able to sense when blood sugar is high and also produce insulin to restore blood sugar healthy levels. A person with type 1 diabetes has a pancreas with poor or no glucose-regulating functions.
“The promise of regenerative medicine is to replace what’s lost in the disease,” said Paul Laikind, President and CEO of Viacyte. “In our case, we’re seeking to replace the beta cell that produces insulin that controls blood glucose. In this way we hope to reduce the burden on patients with type 1 diabetes.”
The Learning Center of Diabetes Management & Supplies (DMS) explains that type 1 diabetes makes up only 5-10 percent of cases diabetes and used to be called juvenile diabetes. Three-quarters of people who develop type 1 are under the age of 18, and most others are under 40 years old, but older adults can also develop it.
The cause of type 1 diabetes is unknown. Most experts believe it is an autoimmune disorder, which is a condition that occurs when the immune system mistakenly attacks and destroys healthy body tissue. With type 1 diabetes, an infection or some other trigger causes the body to destroy the cells in the pancreas that make insulin.
Patients with type 1 diabetes are treated with insulin daily and take it with a syringe, insulin pen, or insulin pump. In addition, they may use a Continuous Glucose Monitoring system (CGM) to monitor their blood glucose constantly. All patients test their blood glucose levels multiple times each day.
DMS offers two options for the various supply needs related to diabetes management. The DMS Product Directory lists some of the products available to those using insurance to get supplies. The new DMS online store provides a secure, efficient setting to make cash sales with the convenience of credit card transactions. There is no need for insurance information or documentation when using the online store.
Customers can also even browse a vast selection of the latest insulin pumps and request a custom quote from the DMS pump staff.
For more on the new type 1 diabetes therapy